Neutropenia develops in a patients undergoing cancer chemotherapy. Administration of which one of the following agents would accelerate recovery of neutrophil counts.
## **Core Concept**
Neutropenia, a condition characterized by abnormally low levels of neutrophils, can be a side effect of cancer chemotherapy. It increases the risk of infections. The management of neutropenia involves the use of agents that can stimulate the production of neutrophils.
## **Why the Correct Answer is Right**
The correct answer, **Filgrastim (G-CSF - Granulocyte-Colony Stimulating Factor)**, works by stimulating the bone marrow to produce more neutrophils. G-CSF is a type of growth factor that specifically promotes the proliferation and differentiation of neutrophil precursors. By administering Filgrastim, the recovery of neutrophil counts can be accelerated, thereby reducing the risk of infections in patients undergoing chemotherapy.
## **Why Each Wrong Option is Incorrect**
- **Option A: Erythropoietin** is used to stimulate red blood cell production in patients with anemia related to chronic disease or chemotherapy. It does not affect neutrophil counts.
- **Option B: Interleukin-2 (IL-2)** is primarily used in immunotherapy to stimulate the proliferation of T cells and has some effects on natural killer cells but is not used to directly stimulate neutrophil production.
- **Option D: Iron dextran** is an iron supplement used to treat iron deficiency anemia. It does not have a role in stimulating neutrophil production.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **G-CSF (Filgrastim)** is specifically used to manage chemotherapy-induced neutropenia. Its administration can significantly reduce the duration of neutropenia and the risk of febrile neutropenia, a potentially life-threatening complication.
## **Correct Answer:** . Filgrastim